Developing an Opioid Taper Intervention Before Total Joint Arthroplasty
RecruitingNot applicableNCT05788016
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: * Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
Study details
- Official title
- Developing and Testing an Opioid Taper Intervention Before Total Knee Arthroplasty: Phase 2 Intervention Development
- Conditions
- Arthritis Knee
- Arthritis Hip
- Chronic Pain
- Interventions
- Behavioral: opioid taper
- Sponsor
- University of Alabama at Birmingham
- Collaborators
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Start date
- 2024-01-10
- Primary completion
- 2026-10-01
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks * currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months * have a reliable telephone number for contact * speaks English Exclusion Criteria: * Taking opioid medications that include: * Buprenorphine * Methadone * Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine) * Transdermal formations of opioid pain medications (e.g., fentanyl patches)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05788016